Palvella (PVLA) Director George M. Jenkins Sells Shares

What Happened
George M. Jenkins, a director of Palvella Therapeutics, sold a total of 27,500 shares in a series of open‑market transactions executed Sept. 11, 14 and 15, 2026. The reported proceeds across the trades total approximately $4.17 million. Individual transactions were reported at per‑share prices ranging roughly from about $148.90 to $153.34 (several sales reported as weighted average prices across multiple executions). These were outright sales (not purchases or option exercises), and the filings note the trades were effected under a Rule 10b5‑1 trading plan.

Key Details

• Transaction dates: Sept. 11, 2026 (multiple sells), Sept. 14, 2026 (multiple sells), and Sept. 15, 2026 (multiple sells).
• Aggregate sold: 27,500 shares for about $4,167,146 total. Per‑trade examples: 6,520 @ $150.62 ($982,035); 6,160 @ $152.12 ($937,034); 5,632 @ $151.46 ($853,037); others listed in the filing.
• Price treatment: Several entries use weighted‑average prices; disclosed execution price ranges across the trades are roughly $148.90–$153.34. The filer offers to provide per‑price breakdowns on request.
• Notable footnotes: trades were made pursuant to a Rule 10b5‑1 plan adopted June 12, 2026 (F1). The filing states profit on 445 shares will be disgorged to the issuer under Section 16 requirements (F2). One footnote references “Eagles Mere Air Museum Foundation” (F12).
• Shares owned after transaction: not specified in the information provided.
• Timeliness: Form 4 filed Sept. 15, 2026; the filing date is within the two business‑day window required for these transaction dates.

Context

• These are planned, open‑market sales under a 10b5‑1 plan, which are commonly used by officers and directors to sell shares for reasons such as tax needs or diversification; such sales do not by themselves indicate company performance.
• Sales are generally less informative than purchases for signaling insider conviction; note the disgorgement note (F2) which may relate to short‑swing profit rules.
• If you track insider activity, this is a sizeable director sale (27.5k shares / ~$4.17M) but was executed under a pre‑arranged plan and reported timely.